BioLineRx Reports Results of BL-8040 in Combination with Keytruda (pembrolizumab) in P-IIb Trial for Patients with Metastatic Pancreatic Cancer
Shots:
- The P-IIa study involves assessing of BL-8040 + Keytruda in 20 patients with metastatic pancreatic cancer who progressed after at least one prior line of chemotherapy
- The overall median time to progression was 2 mos. - while the median time to progression for patients showing disease control was 7 mos. and mOS was 7 mos. - while median survival for the patients showing disease control was 12 mos.- was well-tolerated results plus showed 20% disease control rate
- BL-8040 is a short synthetic peptide acting as an antagonist for a chemokine receptor CXCR4 and is also being evaluated in P-IIa COMBAT/KEYNOTE-202 study in combination with Keytruda and CT for patients with metastatic pancreatic cancer patients. BioLineRx in-licensed BL-8040 from Biokine Therapeutics
Click here to read full press release/ article | Ref: BioLineRx | Image: Twitter
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com